Why the study?
Does imidazo (1,5-2) pyridine-5-hexanoic acid alter platelet aggregation and bleeding time in patients with severe peripheral vascular disease?
Population
Patients with severe peripheral vascular disease selected on the basis of elevated plasma…
Comparison
Imidazo pyridine-5-hexanoic acid vs Control conditions (double-blind, controlled)
Design
RCT, randomized, double-blind
Authors
Loading...
Selective thromboxane synthase inhibition alone may not suffice in severe PVD; challenges monotherapy and supports combined receptor antagonism trials.
Does imidazo (1,5-2) pyridine-5-hexanoic acid alter platelet aggregation and bleeding time in patients with severe peripheral vascular disease?
Selective inhibition of thromboxane synthase does not prevent platelet activation in severe peripheral vascular disease, suggesting that combined receptor antagonism may be necessary.
Reilly et al. (1986) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: